Want to see TMO full AI Analyst Report?
TMO Stock Chart & Stats
$628.15
-$4.06(-0.71%)
At close: 4:00 PM EDT
$628.15
-$4.06(-0.71%)
Day’s Range― - ―
52-Week Range$435.27 - $704.00
Previous CloseN/A
Volume2.94M
Average Volume (3M)2.27M
Market Cap
$255.13B
Enterprise Value$228.94B
Total Cash (Recent Filing)$4.06B
Total Debt (Recent Filing)$42.55B
Price to Earnings (P/E)37.1
Beta0.71
Next Earnings
Oct 21, 2026EPS Estimate
6.4Next Dividend Ex-DateN/A
Dividend Yield0.27%
Share Statistics
EPS (TTM)18.62
Shares Outstanding369,747,280
10 Day Avg. Volume2,310,467
30 Day Avg. Volume2,270,637
Financial Highlights & Ratios
PEG Ratio4.54
Price to Book (P/B)4.08
Price to Sales (P/S)4.89
P/FCF Ratio34.62
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue4.94
Enterprise Value/Gross Profit12.04
Enterprise Value/Ebitda19.79
Forecast
1Y Price Target
$688.31Price Target Upside9.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)25.14
Revenue Forecast (FY)$47.88B
Bulls Say, Bears Say
Bulls Say
Recurring, Diversified Revenue ModelThermo Fisher combines repeat-purchase consumables and services with instrument sales that generate follow-on demand from its installed base. Exposure across pharmaceutical, clinical, academic and industrial customers supports customer retention and reduces dependence on any single end market.
Strong Cash GenerationRobust operating and free cash flow provides internally generated funding for research, acquisitions, debt service and shareholder returns. High earnings conversion also indicates that reported profitability is supported by cash generation, strengthening resilience and capital allocation flexibility.
Raised Outlook With Margin ExpansionThe raised outlook signals improving operating execution, with expected organic growth, higher adjusted EPS and margin expansion. If achieved, this combination can reinforce earnings momentum and demonstrate that productivity and volume leverage are offsetting mix and market-related pressures.
Bears Say
Elevated Leverage And Financing CostLeverage has become a meaningful constraint on financial flexibility, while interest expense absorbs cash that could otherwise fund investment or returns. Higher debt also increases sensitivity to financing conditions and leaves less room to absorb weaker demand or execution setbacks.
Margins Remain Below Prior LevelsAlthough profitability remains substantial, the decline from earlier gross and net margin levels indicates that earnings power has not fully recovered. Persistent mix or cost pressure could limit operating leverage and make future profit growth more dependent on revenue expansion.
Muted Academic, Government And China DemandWeakness in academic, government and parts of China creates a durable demand headwind across research-related workflows. An uneven funding recovery can delay instrument and consumable purchases, limiting organic growth and reducing the consistency of the company’s end-market expansion.
Thermo Fisher News
TMO FAQ
What was Thermo Fisher’s price range in the past 12 months?
Thermo Fisher lowest stock price was $435.27 and its highest was $704.00 in the past 12 months.
What is Thermo Fisher’s market cap?
Thermo Fisher’s market cap is $255.13B.
When is Thermo Fisher’s upcoming earnings report date?
Thermo Fisher’s upcoming earnings report date is Oct 21, 2026 which is in 2 days.
How were Thermo Fisher’s earnings last quarter?
Thermo Fisher released its earnings results on Jul 23, 2026. The company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.719 by $0.311.
Is Thermo Fisher overvalued?
According to Wall Street analysts Thermo Fisher’s price is currently Undervalued.
Does Thermo Fisher pay dividends?
Thermo Fisher pays a Quarterly dividend of $0.47 which represents an annual dividend yield of 0.27%. See more information on Thermo Fisher dividends here
What is Thermo Fisher’s EPS estimate?
Thermo Fisher’s EPS estimate is 6.4.
How many shares outstanding does Thermo Fisher have?
Thermo Fisher has 369,747,280 shares outstanding.
What happened to Thermo Fisher’s price movement after its last earnings report?
Thermo Fisher reported an EPS of $6.03 in its last earnings report, beating expectations of $5.719. Following the earnings report the stock price went up 8.711%.
Which hedge fund is a major shareholder of Thermo Fisher?
Currently, no hedge funds are holding shares in TMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Thermo Fisher Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$688.31 (9.58% Upside)
$688.31 (9.58% Upside)
Blogger Sentiment
Bullish
TMO Sentiment 75%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 3.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.99%
12-Months-Change
Fundamentals
Return on Equity
13.35%
Trailing 12-Months
Asset Growth
11.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Thermo Fisher
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
TMO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational execution: double-digit reported revenue growth, a clean beat to prior guidance, margin expansion, robust free cash flow, successful acquisition integration, numerous product launches and an upward revision to full-year guidance. The primary negatives were modest and manageable: the planned microbiology divestiture (small near-term revenue and EPS drag and future dilution), lingering softness in certain end markets (academic/government and parts of China), some unfavorable product mix impacts, a reduced FX tailwind and elevated leverage. Overall, the positives in the quarter — including beats, guidance raise, margin expansion and strong cash generation — substantially outweigh the lowlights.View all TMO earnings summariesTMO Revenue Breakdown
54.01% Laboratory Products and Biopharma Services
22.46% Life Sciences Solutions
17.40% Analytical Instruments
10.52% Specialty Diagnostics
TMO Stock 12 Month Forecast
Average Price Target
$688.31
▲(9.58% Upside)
Technical Analysis
Ownership Overview
0.13% Insiders
24.31% Mutual Funds
1.26% Other Institutional Investors
53.13% Public Companies and Individual Investors